Back to Search
Start Over
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.
- Source :
-
Oncoimmunology [Oncoimmunology] 2018 May 29; Vol. 7 (12), pp. e1460298. Date of Electronic Publication: 2018 May 29 (Print Publication: 2018). - Publication Year :
- 2018
-
Abstract
- We report the immunological profile of a patient with upper-tract urothelial carcinoma experiencing stable disease on pembrolizumab for 20 months. The tumor exhibited extensive infiltration by CD8 <superscript>+</superscript> cytotoxic T lymphocytes, low-to-moderate mutational burden, no PD-L1 staining by commercially available immunohistochemical assays, but amplification of CD274 (coding for PD-L1) and/or PDCD1LG2 (encoding PD-L2) by fluorescence in situ hybridization. RNA-seq revealed multiple biomarkers of an ongoing immune response and compensatory immune evasion, including moderate PD-L1 levels coupled with robust PD-L2 expression. Pending validation in additional patients, these findings suggest that PD-L2 expression levels may constitute a biomarker of response to immune checkpoint blockade in urothelial carcinoma.
Details
- Language :
- English
- ISSN :
- 2162-4011
- Volume :
- 7
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Oncoimmunology
- Publication Type :
- Academic Journal
- Accession number :
- 30524881
- Full Text :
- https://doi.org/10.1080/2162402X.2018.1460298